ARDX — Ardelyx, Inc.

Summary of Ardelyx Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $110.3 million, a 12% increase year-over-year from $98.2 million.
• IBSRELA Revenue: $78.2 million, up 92% year-over-year, marking a record quarter.
• XPHOZAH Revenue: $27.4 million, a 9% increase from Q2 2025.
• Gross to Net Deductions: Approximately 31% for IBSRELA and 29% for XPHOZAH.
• Net Loss: Approximately $1 million, or less than $0.01 per share, compared to a loss of $800,000 in Q3 2024.
• Cash Position: $242.7 million in cash, cash equivalents, and short-term investments.

2. Strategic Updates and Business Highlights

• IBSRELA: Continues to be the main growth driver, with strong demand and engagement from prescribers. The company is raising its revenue guidance for IBSRELA to $270-$275 million for the year.
• XPHOZAH: The team is focused on ensuring patient access and driving prescription growth. The revenue growth is attributed to improved clinical conviction among nephrologists and effective marketing strategies.
• Pipeline Development: Introduction of ARDX-10531 (531), a next-generation NHE3 inhibitor, with preclinical development underway. This marks Ardelyx's first new development program in over three years.
• Leadership Changes: Sue Hohenleitner has joined as Chief Financial Officer, succeeding Justin Renz, who is transitioning out of the role.

3. Forward Guidance and Outlook

• IBSRELA: Expected to generate between $270 million and $275 million in revenue for 2025, reflecting confidence in continued growth.
• XPHOZAH: Long-term peak revenue guidance remains at $750 million, with ongoing efforts to expand prescriber engagement and patient access.
• Overall Strategy: Ardelyx aims to leverage its strong cash position to invest in commercial activities and pipeline development.

4. Bad News, Challenges, or Points of Concern

• Market Competition: IBSRELA is positioned as a second-line therapy, facing competition from established first-line treatments like Linzess. The company acknowledges the challenge of increasing its first-line market share.
• XPHOZAH's Market Dynamics: The company experienced a significant revenue loss in the past due to market turmoil, which could impact future growth despite recent gains.
• Regulatory and Development Risks: The development of 531 is still in early stages, and its success is uncertain, particularly regarding its potential indications and market acceptance.

5. Notable Q&A Insights

• IBSRELA Market Positioning: Management emphasized that while IBSRELA is not currently positioned as a first-line therapy, there is significant organic growth potential due to high patient dissatisfaction with existing treatments.
• Pipeline Expansion: Questions regarding the new 531 molecule highlighted the potential for broader indications, but management stressed the need for cautious, step-by-step development.
• Sales Force Strategy: There is ongoing consideration of expanding the sales force further to maximize growth opportunities, although current strategies are yielding positive results.
• Market Perception: Management expressed concerns that the market may be undervaluing Ardelyx's growth potential, particularly regarding IBSRELA, and emphasized the importance of demonstrating consistent performance to gain investor confidence.

Overall, Ardelyx's Q3 2025 results reflect strong growth driven by IBSRELA, with strategic initiatives in place to enhance its product portfolio and pipeline, despite facing competitive pressures and market uncertainties.